MolecuLight Featured in 8 Presentations and Posters at Wounds Australia 2022 Conference

September 13, 2022 -Wide-Spread Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates its Significant Global Adoption and Proven Utility in Wound Care

Toronto, CANADA and Sydney, AUSTRALIA – (September 13, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that its

Read More

Newly Published RCT Shows MolecuLight Fluorescence Point-of-Care Imaging Improved 12-Week Wound Healing by 204% in Diabetic Foot Ulcers

July 13, 2022 -Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods

Leeds, UK and Toronto, CANADA – (July 13, 2022) MolecuLight Inc., the leader in fluorescence imaging for detection and localization of

Read More

FDA 510(k) Clearance Expands Labelling of MolecuLight i:X® to Include the Ability to Identify Regions Containing Elevated Load and More Bacterial Species

June 29, 2022 -New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect Clinically Significant Bacteria that Impedes Wound Healing

TORONTO, CANADA – (June 29, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion

Read More

MolecuLight Added to the ISWCAP 2022 Consensus Guidelines for Optimising Prevention of Surgical Wound Complications

June 1, 2022 -Authors of International Consensus Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management

Toronto, CANADA and London, UK – (June 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced

Read More